Document:

Exhibit 10.1

 

VOTING AND SUPPORT AGREEMENT

 

This VOTING AND SUPPORT AGREEMENT
(this “Agreement”) is entered into as of December 15, 2021, by and among:

 

		1.	Blue Safari Group Acquisition Corp., a British Virgin Islands business company (“SPAC”);

 

		2.	Bitdeer Technologies Group, an exempted company incorporated with limited liability under the Laws of
Cayman Islands (the “PubCo”);

 

		3.	Bitdeer Technologies Holding Company, an exempted company incorporated with limited liability under the
Laws of the Cayman Islands (the “Company”); and

 

		4.	each shareholder of the Company listed in the column titled “Supporting Shareholder”
in Schedule A attached hereto (each, a “Supporting Shareholder”).

 

Capitalized terms used but not
defined herein shall have the meanings ascribed to such terms in the A&R Merger Agreement (as defined below).

 

RECITALS

 

WHEREAS, SPAC, Blue Safari
Mini Corp., an exempted company with limited liability incorporated under the Law of the Cayman Islands and a wholly-owned Subsidiary
of SPAC (“SPAC Sub”), the Company, PubCo, Blue Safari Merge Limited, a British Virgin Islands business company and
a wholly-owned subsidiary of PubCo (“Merger Sub 1”), Blue Safari Merge II Limited, a British Virgin Islands business
company and a wholly-owned subsidiary of PubCo (“Merger Sub 2”) and Bitdeer Merge Limited, an exempted company with
limited liability incorporated under the laws of the Cayman Islands and a wholly-owned subsidiary of PubCo (“Merger Sub 3”)
have, concurrently with the execution of this Agreement, entered into an Amended and Restated Agreement and Plan of Merger, dated as of
the date hereof (as may be amended, supplemented or otherwise modified from time to time, the “A&R Merger Agreement”).

 

WHEREAS, as of the date
hereof, each Supporting Shareholder is the record and beneficial owner of and/or have the voting power (whether or not through a proxy)
over, the number of the Company Shares set forth opposite such Supporting Shareholder’s name on Schedule A under the column
heading “Subject Shares” (all such Company Shares, together with any other Company Shares (including
any securities convertible into or exercisable or exchangeable for any Company Shares, including
for the avoidance of doubt, the Company Options) of which beneficial and/or record ownership and/or the voting power (whether or
not through a proxy) is hereafter acquired by any such Supporting Shareholder during the period from the date hereof through the Expiration
Time are collectively referred to herein as the “Covered Shares”);

 

WHEREAS, in order to
induce SPAC, SPAC Sub, PubCo, Merger Sub 1, Merger Sub 2 and Merger Sub 3 to enter into the A&R Merger Agreement and consummate the
transactions contemplated thereby, including the Mergers, the Supporting Shareholders are entering into this Agreement; and

 

     

     

    

 

WHEREAS, the Supporting
Shareholders acknowledge that SPAC, SPAC Sub, PubCo, Merger Sub 1, Merger Sub 2 and Merger Sub 3 are entering into the A&R Merger
Agreement in reliance on the representations, warranties, covenants and other agreements of the Supporting Shareholders set forth in this
Agreement.

 

NOW, THEREFORE, in consideration
of the foregoing, the mutual covenants and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the parties hereto agree as follows:

 

		1.	Definitions.

 

When used in this Agreement,
the following terms in all of their tenses, cases and correlative forms shall have the meanings assigned to them in this Section 1.

 

“Expiration Time”
shall mean the earlier to occur of (a) the Acquisition Merger Effective Time, (b) such date and time as the A&R Merger Agreement shall
be terminated in accordance with its terms, and (c) as to any Supporting Shareholder, the Termination Date.

 

“Transfer”
shall mean any sale, assignment, encumbrance, pledge, hypothecation, disposition, loan or other transfer, or entry into any Contract,
option or other arrangement or understanding with respect to any sale, assignment, encumbrance, pledge, hypothecation, disposition, loan
or other transfer, in each case directly or indirectly and voluntarily or involuntarily, of any interest owned by a Person or any interest
(including a beneficial interest) in, or the ownership, control or possession of, any interest owned by a Person, excluding entry into
this Agreement and the A&R Merger Agreement and the consummation of the transactions contemplated hereby and thereby.

 

		2.	Agreement to Vote.

 

From and after the date hereof
until the Expiration Time, each of the Supporting Shareholders irrevocably and unconditionally agrees that at any meeting of the shareholders
of the Company (whether annual or special and whether or not an adjourned or postponed meeting, however called and including any adjournment
or postponement thereof) and in connection with any written consent of the shareholders of the Company, such Supporting Shareholder shall:

 

(a)               when
such meeting is held, appear at such meeting or otherwise cause such Supporting Shareholder’s Covered Shares to be counted as present
thereat for the purpose of establishing a quorum;

 

(b)              
vote (or execute and return an action by written consent), or cause to be voted at such meeting (or validly execute and return
and cause such consent to be granted with respect to), all of such Supporting Shareholder’s Covered Shares owned as of the record
date for such meeting (or the date that any written consent is executed by such Supporting Shareholder) in
favor of the Mergers and the adoption of the A&R Merger Agreement and any other matters necessary or reasonably requested by SPAC,
PubCo or the Company for consummation of the Mergers and the other transactions contemplated by the A&R Merger Agreement;

 

    2

     

    

 

(c)               
 in any other circumstances upon which a consent or other approval is required under the Company’s Organizational Documents,
or otherwise sought with respect to the A&R Merger Agreement or the other transactions contemplated by the A&R Merger Agreement,
vote, consent or approve (or cause to be voted, consented or approved) all of such Supporting Shareholder’s Covered Shares held
at such time in favor thereof;

 

(d)              
vote (or execute and return an action by written consent), or cause to be voted at such meeting (or validly execute and return
and cause such consent to be granted with respect to), all of such Supporting Shareholder’s Covered Shares against (i) any Alternative
Transction and (ii) any and all other proposals or actions that would reasonably be expected to (x) impede, interfere with, delay, postpone
or adversely affect the Mergers or any of the other transactions contemplated by the A&R Merger Agreement, or (y) result in any of
the closing conditions of the Company, the SPAC Parties or the Acquisition Entities under the A&R Merger Agreement not being satisfied,
or otherwise result in a breach of any of the representations, warranties, covenants or other obligations or agreements of the Company,
the SPAC Parties or the Acquisition Entities under the A&R Merger Agreement.

 

No Supporting Shareholder shall
take or omit to take, or commit or agree to take or omit to take any action inconsistent with the foregoing that would be effective prior
to the Expiration Time.

 

		3.	Agreement to Retain Covered Shares.

 

3.1.          Restrictions on Transfers.

 

Each of the Supporting Shareholders
hereby agrees that, from the date hereof until the Expiration Time, such Supporting Shareholder shall not, and shall cause its or his
Affiliates not to, directly or indirectly:

 

(a)              
Transfer the Covered Shares or any interest therein, or publicly announce any intention
to effect any such transactions;

 

(b)              
engage in any hedging or other transaction which is designed to, or which would (either alone or in connection with one or more
events, developments or events (including the satisfaction or waiver of any conditions precedent)), lead to or result in a sale or disposition
of such Supporting Shareholder’s Covered Shares;

 

(c)              
enter into any voting agreement or voting trust with respect to any of such Supporting Shareholder’s Covered Shares that
is inconsistent with such Supporting Shareholder’s obligations pursuant to this Agreement, or grant any proxy or power of attorney
with respect to any of such Supporting Shareholder’s Covered Shares that is inconsistent with such Supporting Shareholder’s
obligations pursuant to this Agreement, or enter into enter into any agreement or undertaking that is otherwise inconsistent with, or
would interfere with, or prohibit or prevent such Supporting Shareholder from satisfying its or his obligations pursuant to this Agreement;

 

    3

     

    

 

(d)               take
any action that would make any representation or warranty of such Supporting Shareholder set forth in this Agreement untrue or
incorrect, or would otherwise have the effect of preventing, disabling, or delaying the performing of such Supporting Holder’s
obligations hereunder; or

 

(e)              
agree (whether or not in writing) to take any of the actions referred to in the foregoing clauses (a), (b), (c) or (d).

 

3.2.          Additional
Purchases. 

 

Until the Expiration Time,
each Supporting Shareholder agrees that any Covered Shares (including any securities convertible
into or exercisable or exchangeable for any Covered Shares, including for the avoidance of doubt, the Company Options) that such
Supporting Shareholder purchases, that are issued to such Supporting Shareholder by the Company, that are otherwise hereinafter acquired
by such Supporting Shareholder or with respect to which such Supporting Shareholder otherwise acquires the voting power (whether or not
through a proxy) after the date hereof and prior to the Expiration Time, shall in each case be subject to the terms and conditions of
this Agreement to the same extent as if they were Covered Shares owned by such Supporting Shareholder as of the date hereof. Each of the
Supporting Shareholders agrees, while this Agreement is in effect, to notify SPAC, PubCo and the Company promptly in writing of the number
of any additional Covered Shares acquired, or over which voting power is acquired, by such Supporting Shareholder, if any, after the date
hereof.

 

3.3.          Unpermitted Transfers.

 

Any Transfer or attempted
Transfer of any Covered Shares in violation of the Section 3.1 shall, to the fullest extent permitted by applicable Law,
be null and void ab initio.

 

		4.	Additional Agreements.

 

4.1.          Rights
under the A&R Merger Agreement. 

 

For the avoidance of doubt,
the Company does not, by signing this Agreement, waive any of the rights it is otherwise entitled to under the A&R Merger Agreement,
and nothing in this Agreement shall be construed to limit the ability of the Company to enforce its rights under the A&R Merger Agreement.

 

4.2.          Binding
Effect of the A&R Merger Agreement.

 

Each of the Supporting Shareholders
hereby acknowledges that it has read the A&R Merger Agreement and this Agreement and has had the opportunity to consult with its tax
and legal advisors. Each Supporting Shareholder shall be bound by and comply with Section 8.1(d), Section 10.5, and Section 14.4 of the
A&R Merger Agreement (and any relevant definitions contained in any such sections) as if (x) such Supporting Shareholder was an original
signatory to the A&R Merger Agreement with respect to such provisions, and (y) each reference to the “Company Group” contained
in such provisions also referred to each such Supporting Shareholders.

 

    4

     

    

 

4.3.          Appraisal;
Dissenters’ Rights. 

 

Each Supporting Shareholder
agrees to refrain from exercising any dissenters’ rights or rights of appraisal under applicable Law at any time with respect to
the A&R Merger Agreement, the Additional Agreements and the transactions contemplated thereby.

 

Each Supporting Shareholder
further agrees not to commence or participate in, and to take all actions necessary to opt out of any class in any class action with respect
to, any action or claim, derivative or otherwise, against SPAC, SPAC’s Affiliates, any of SPAC’s officers or directors, the
Sponsor, the Company or any of their respective successors and assigns relating to the negotiation, execution or delivery of this Agreement,
the A&R Merger Agreement or the consummation of the transactions contemplated hereby and thereby, including any claim (x) challenging
the validity of, or seeking to enjoin the operation of, any provision of this Agreement or the A&R Merger Agreement, or (y) alleging
a breach of any fiduciary duty of the board of directors of the Company in connection with this Agreement, the A&R Merger Agreement
or the transactions contemplated hereby and thereby.

 

4.4.          Corporate
Change.

 

In the event of any equity dividend
or distribution, or any change in the equity interests of the Company by reason of any equity dividend or distribution, equity split,
recapitalization, combination, conversion, exchange of equity interests or the like, the term “Covered Shares” shall be deemed
to refer to and include the Covered Shares as well as all such equity dividends and distributions and any securities into which or for
which any or all of the Covered Shares may be changed, converted or exchanged or which are received in such transaction.

 

4.5.          Further
Assurance.

 

From time to time, at SPAC’s,
PubCo’s or the Company’s request and without further consideration, each Supporting Shareholder shall execute and deliver
such additional documents and take all such further action as may be reasonably necessary or reasonably requested to effect the actions
and consummate the transactions contemplated by this Agreement and the A&R Merger Agreement.

 

4.6.          Consent to Disclosure.

 

Each of the Supporting Shareholders
hereby consents to the publication and disclosure in the Proxy Statement (and, as and to the extent otherwise required by applicable securities
Laws or the SEC or any other securities authorities, any other documents or communications provided by SPAC, PubCo or the Company to any
Authority or to securityholders of SPAC) of such Supporting Shareholder’s identity and beneficial ownership of the Covered Shares,
and the nature of such Supporting Shareholder’s commitments, arrangements and understandings under and relating to this Agreement
and, if deemed appropriate by SPAC, PubCo or the Company, a copy of this Agreement. Each of the Supporting Shareholders shall promptly
provide any information reasonably requested by SPAC, PubCo or the Company for any regulatory application or filing made or approval sought
in connection with this Agreement, the A&R Merger Agreement or the consummation of the transactions contemplated hereby and thereby
(including filings with the SEC).

 

    5

     

    

 

		5.	Representations, Warranties and Covenants of the Supporting Shareholders

 

Each of the Supporting Shareholders,
severally and not jointly, represents and warrants to SPAC and PubCo that:

 

(a)               
Ownership of Covered Shares. Such Supporting Shareholder is the sole record and beneficial owner (within the meaning
of Rule 13d-3 under the Exchange Act) of, and has good, valid and marketable title to or has a valid proxy or power of attorney to vote
all of such Supporting Shareholder’s Covered Shares, free and clear of any Liens. As of the date hereof, other than the number and
type of the shares set forth opposite such Supporting Shareholder’s name on Schedule A, such Supporting Shareholder does
not own beneficially or of record or have the voting power over any other Company Shares (or any
securities convertible into or exercisable or exchangeable for any Company Shares)
or any interest therein.

 

(b)              
Authority; Organization. Such Supporting Shareholder (i) has full voting power, full power of disposition and full
power to issue instructions with respect to the matters set forth herein, whether by ownership or by proxy, in each case, with respect
to such Supporting Shareholder’s Covered Shares, (ii) has not entered into any voting agreement or voting trust, and has no knowledge
and is not aware of any such voting agreement or voting trust in effect with respect to any of such Supporting Shareholder’s Covered
Shares that is inconsistent with such Supporting Shareholder’s obligations pursuant to this Agreement, (iii) has not granted any
proxy or power of attorney with respect to any of such Supporting Shareholder’s Covered Shares that is inconsistent with such Supporting
Shareholder’s obligations pursuant to this Agreement, and has no knowledge and is not aware of any such proxy or power of attorney
in effect, and (iv) has not entered into any agreement or undertaking that is otherwise inconsistent with, or would interfere with, or
prohibit or prevent such Supporting Shareholder from satisfying, its or his obligations pursuant to this Agreement, and has no knowledge
and is not aware of any such agreement or undertaking.

 

Such Supporting Shareholder
affirms that (i) if such Supporting Shareholder is a natural person, he or she has all the requisite power and authority and has taken
all actions necessary in order to execute and deliver this Agreement, to perform his or her obligations hereunder and to consummate the
transaction contemplated hereby, and (ii) if such Supporting Shareholder is not a natural person, such Supporting Shareholder (A) is a
legal entity duly organized, validly existing and, to the extent such concept is applicable, in good standing under the Laws of the jurisdiction
of its organization, and (B) has all requisite corporate or other power and authority and has taken all corporate or other action necessary
in order to execute, deliver and perform its obligations under this Agreement and to consummate the transactions contemplated hereby.
This Agreement has been duly executed and delivered by such Supporting Shareholder, and constitutes a legally valid and binding agreement
of such Supporting Shareholder, enforceable against such Supporting Shareholder in accordance with the terms hereof (except as enforceability
may be limited by bankruptcy Laws or other similar Laws affecting creditors’ rights and general principles of equity affecting the
availability of specific performance and other equitable remedies).

 

    6

     

    

 

(c)                No
Conflict; Consent. The execution, delivery and performance of this Agreement by such Supporting Shareholder does not, and
the consummation of the transactions contemplated hereby and the Mergers and the other transactions contemplated by the A&R
Merger Agreement will not, constitute or result in (i) a breach or violation of, or a default under, the Organizational Documents of
such Supporting Shareholder (if such Supporting Shareholder is not a natural person), (ii) with or without notice, lapse of time or
both, a breach or violation of, a termination (or right of termination) of or a default under, the loss of any benefit under, the
creation, modification or acceleration of any obligations under or the creation of a Lien on any of the properties, rights or assets
of such Supporting Shareholder pursuant to any Contract binding upon such Supporting Shareholder or, assuming (solely with respect
to performance of this Agreement and the transactions contemplated hereby) compliance with the matters referred to in Section
5(d), under any applicable Law to which such Supporting Shareholder is subject or (iii) any change in the rights or obligations
of any party under any Contract legally binding upon such Supporting Shareholder.

 

Other than the filings, notices
and reports pursuant to, in compliance with or required to be made under the Exchange Act, no filings, notices, reports, consents, registrations,
approvals, permits, waivers, expirations of waiting periods or authorizations are required to be obtained by such Supporting Shareholder
from, or to be given by such Supporting Shareholder to, or be made by such Supporting Shareholder with, any Authority or any other Person
in connection with the execution, delivery and performance by such Supporting Shareholder of this Agreement, the consummation of the transactions
contemplated hereby or the Mergers or the other transactions contemplated by the A&R Merger Agreement.

 

(d)              
Absence of Litigation. As of the date of this Agreement, there is no action, proceeding or investigation pending
or threatened against such Supporting Shareholder that in any manner questions the beneficial or record ownership of the Supporting Shareholder’s
Covered Shares or the validity of this Agreement, or challenges or seeks to prevent, enjoin or delay the performance by such Supporting
Shareholder of its or his obligations under this Agreement.

 

(e)               Supporting
Shareholders Has Adequate Information. The Supporting Shareholder is a sophisticated shareholder and has adequate information
concerning the business and financial condition of the SPAC, PubCo and the Company to make an informed decision regarding this Agreement
and the other transactions contemplated by the A&R Merger Agreement, and has independently and based on such information as the Supporting
Shareholder has deemed appropriate, made its own analysis and decision to enter into this Agreement. The Supporting Shareholder acknowledges
that SPAC, PubCo and the Company have not made and do not make any representation or warranty, whether express or implied, of any kind
or character except as expressly set forth in this Agreement. The Supporting Shareholder acknowledges that the agreements contained herein
with respect to the Covered Shares held by the Supporting Shareholder are irrevocable.

 

    7

     

    

 

		6.	Termination

 

This Agreement, and the
obligations of a Supporting Shareholder hereunder shall terminate and be of no further force or effect immediately upon the first to
occur of (a) the Acquisition Merger Effective Time, (b) termination of the A&R Merger Agreement in accordance with its terms,
and (c) the written agreement of such Supporting Shareholder on one hand, and SPAC and PubCo on the other hand (such date, the
 “Termination Date”); provided, that this Section 6 and Section 7 shall survive any
termination of this Agreement. Nothing in this Section 6 shall relieve or otherwise limit any party’s liability for any
breach of this Agreement prior to the termination of this Agreement.

 

		7.	Miscellaneous

 

7.1.          Notices.

 

All notices and other communications
hereunder shall be in writing and shall be deemed to have been duly given when delivered in person or upon confirmation of receipt when
transmitted by facsimile transmission or by electronic mail or on the next business day if transmitted by international overnight courier,
in each case to the respective parties at the address set forth below (or at such other address for a party as shall be specified in a
notice given in accordance with this Section 7.1):

 

if to the Company:

 

Bitdeer Technologies Holding Company

08 Kallang Avenue

Aperia tower 1, #09-03/04

Singapore 339509

Attn: Linghui Kong

Email: linghui.kong@bitdeer.com

 

with a copy (which shall not constitute notice) to:

 

Cooley LLP

55 Hudson Yards

New York, New York 10001

Attn: Will H. Cai

Email: wcai@cooley.com

 

if to any SPAC and
SPAC Sub:

 

Blue Safari Group Acquisition Corp.

Cheung Kong Center,

58 Floor, Unit 5801

2 Queens Road Central

Central

Hong Kong

Attn: Serena Shie

Email: serena@firsteuro.co

 

    8

     

    

 

with a copy (which shall not constitute notice) to:

 

Davis Polk & Wardwell LLP

450 Lexington Avenue

New York, NY 10017

Attn: Howard Zhang

Email: howard.zhang@davispolk.com

 

if to PubCo:

 

Travers Thorp Alberga, Attorneys at Law

Harbour Place, 2nd Floor

PO Box 472

103 South Church Street

Grand Cayman, KY1-1106, Cayman Islands

Email: rthorp@traversthorpalberga.com

Attention: Richard Thorp

 

with a copy (which shall not constitute notice) to:

 

Cooley LLP

55 Hudson Yards

New York, New York 10001

Attn: Will H. Cai

Email: wcai@cooley.com

 

with a copy (which shall not constitute notice) to:

 

Davis Polk & Wardwell LLP

450 Lexington Avenue

New York, NY 10017

Attn: Howard Zhang

Email: howard.zhang@davispolk.com

 

if to Victory Courage
Limited:

 

08 Kallang Avenue

Aperia tower 1, #09-03/04

Singapore 339509

Attn: Jihan Wu

Email: jihan.wu@bitdeer.com

 

7.2.          Severability.

 

If any provision of this
Agreement is held to be invalid or unenforceable for any reason, it shall be adjusted rather than voided, if possible, in order to
achieve the intent of the parties to the maximum extent possible. In any event, the invalidity or unenforceability of any provision
of this Agreement in any jurisdiction shall not affect the validity or enforceability of the remainder of this Agreement in that
jurisdiction or the validity or enforceability of this Agreement, including that provision, in any other jurisdiction.

 

    9

     

    

 

7.3.          Entire
Agreement.

 

This Agreement, the A&R
Merger Agreement, the Additional Agreements and the other agreements contemplated hereby and thereby, constitute the entire agreement
among the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and undertakings, both written
and oral, among the parties, or any of them, with respect to the subject matter hereof.

 

7.4.          Specific
Performance.

 

Each of the parties hereto acknowledge
and agree that the other parties would be irreparably injured by a breach of this Agreement by it and that money damages alone would not
be an adequate remedy for any actual or threatened breach of this Agreement. Accordingly, each party shall be entitled to specific performance
or injunctive or other equitable relief (without posting a bond or other security) to enforce or prevent any violations of any provision
of this Agreement, in addition to all other rights and remedies available at law or in equity to such party, including the right to claim
money damages for breach of any provision of this Agreement. All rights, powers, and remedies provided under this Agreement or otherwise
available in respect hereof at law or in equity shall be cumulative and not alternative, and the exercise or beginning of the exercise
of any thereof by a party shall not preclude the simultaneous or later exercise of any other such right, power or remedy by a party.

 

7.5.          Amendments;
Waivers.

 

At any time prior to the Expiration
Time, any provision of this Agreement may be amended or waived if, and only if such amendment or waiver is in writing and signed, in the
case of an amendment, by the Supporting Shareholders, SPAC and PubCo, or in the case of a waiver, by the party against whom the waiver
is to be effective. Notwithstanding the foregoing, no failure or delay by a party hereto in exercising any right hereunder shall operate
as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise of any other right hereunder.

 

7.6.          Governing
Law; Jurisdiction.

 

The provisions of Article XII
(Dispute Resolution) and Section 14.7 (Governing Law) of the A&R Merger Agreement are hereby incorporated herein by reference, mutatis
mutandis.

 

7.7.          Third Party Beneficiaries.

 

There are no third party beneficiaries
of this Agreement and nothing in this Agreement, express or implied, is intended to confer on any Person other than the parties hereto
(and their respective successors, heirs and permitted assigns), any rights, remedies, obligations or liabilities, except as specifically
set forth in this Agreement.

 

    10

     

    

 

 

7.8.          Assignment; Binding Effect.

 

Neither this Agreement nor any
of the rights, interests or obligations hereunder shall be assigned by any of the parties hereto (whether by operation of Law or otherwise)
without the prior written consent of the other parties, except that SPAC and PubCo may assign this Agreement (in whole but not in part)
in connection with a permitted assignment of the A&R Merger Agreement by SPAC or PubCo, as applicable. Subject to the preceding sentence,
this Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted
assigns and, in the case of each Supporting Shareholder, its or his estate, heirs, beneficiaries, personal representatives and executors.

 

7.9.          No
Presumption Against Drafting Party.

 

Each of the parties to this
Agreement acknowledges that it has been represented by independent counsel in connection with this Agreement and the transactions contemplated
by this Agreement. Accordingly, any rule of Law or any legal decision that would require interpretation of any claimed ambiguities in
this Agreement against the drafting party has no application and is expressly waived.

 

7.10.        Interpretation.

 

When a reference is made in
this Agreement to a Section or a Schedule such reference shall be to a Section or a Schedule of this Agreement unless otherwise indicated.
The headings contained in this Agreement are for convenience of reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances
require. The word “including” and words of similar import when used in this Agreement will mean “including, without
limitation”, unless otherwise specified. The words “hereof”, “herein” and “hereunder” and words
of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement.
The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms and to the masculine
as well as to the feminine and neuter genders of such term. Any agreement, instrument or statute defined or referred to herein or in any
agreement or instrument that is referred to herein means such agreement, instrument or statute as from time to time amended, modified
or supplemented, including (in the case of agreements or instruments) by waiver or consent and (in the case of statutes) by succession
of comparable successor statutes and references to all attachments thereto and instruments incorporated therein. References to a Person
are also to its permitted successors and assigns. References to clauses without a cross-reference to a Section or subsection are references
to clauses within the same Section or, if more specific, subsection. References from or through any date shall mean, unless otherwise
specified, from and including or through and including, respectively. The symbol “US$” refers to United States Dollars. The
word “extent” in the phrase “to the extent” means the degree to which a subject or other thing extends and such
phrase shall not mean simply “if”. References to “day” shall mean a calendar day unless otherwise indicated as
a “Business Day”.

 

7.11.        Counterparts.

 

This Agreement may be executed
in counterparts and all counterparts taken together shall constitute one document. E-mailed copies of signatures shall be deemed to be
originals for purposes of the effectiveness of this Agreement.

 

[Signature Pages Follow]

 

    11

     

    

 

IN WITNESS WHEREOF, the
parties hereto have duly executed and delivered this Agreement as of the date and year first written above.

 

	 	Blue
    Safari Group Acquisition Corp.
	 	 
	 	By:	/s/ Naphat Sirimongkolkasem
	 	Name:
    Naphat Sirimongkolkasem
	 	Title:
    Director

 

[Signature Page to Voting and Support Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, the
parties hereto have duly executed and delivered this Agreement as of the date and year first written above.

 

	 	Bitdeer
    Technologies Group
	 	 
	 	By:	/s/ Clara Jiang
	 	Name:
    Clara Jiang
	 	Title:
    Director

 

[Signature Page to Voting and Support Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, the
parties hereto have duly executed and delivered this Agreement as of the date and year first written above.

 

	 	Bitdeer Technologies Holding Company
	 	 
	 	By:	/s/ WU Jihan
	 	Name: WU Jihan 吴忌寒
	 	Title: Director

 

[Signature Page to Voting and Support Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, the
parties hereto have duly executed and delivered this Agreement as of the date and year first written above.

 

	 	Victory Courage Limited
	 	 
	 	By:	/s/ WU Jihan
	 	Name: WU Jihan 吴忌寒
	 	Title: Director

 

[Signature Page to Voting and Support Agreement]

 

     

     

    

 

SCHEDULE A

 

Schedule of Supporting Shareholders

 

	Supporting Shareholders	 	Type of Subject Shares	 	Number of Subject Shares	 
	Victory Courage Limited	 	Class B Ordinary	 	 	5,631,795,619	 
	Victory Courage Limited	 	Series A Preferred	 	 	7,141,236Exhibit 4.4

 

WARRANT AGREEMENT

 

This
Warrant Agreement (“Warrant Agreement”) is made as of [•], 2021, by and between Gardiner Healthcare Acquisitions
Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company (the “Warrant
Agent”).

 

WHEREAS, the Company is engaged
in a public offering (the “Public Offering”) of 7,500,000 units (the “Units”) of the Company (and
up to 1,125,000 additional Units to the extent that the underwriters’ over-allotment option is exercised), each Unit consisting
of one share of common stock, par value $0.0001 per share (the “Common Stock”) and one warrant (the “Public
Warrant” or “Public Warrants”), each Public Warrant entitling its holder to purchase one share of Common
Stock (the “Public Warrant Shares”);

 

WHEREAS,
the Company has filed with the Securities and Exchange Commission (the “SEC”) a Registration Statement on Form S-1,
File No. 333-[•] (“Registration Statement”), and a prospectus (the
 “Prospectus”), for the registration, under the Securities Act of 1933, as amended (“Securities Act”),
of, among other securities, the Public Warrants;

 

WHEREAS,
the Company has received a binding commitment from Gardiner Healthcare Holdings, LLC to purchase up to 3,632,813 warrants, Chardan Gardiner
LLC to purchase up to 622,767 warrants, and CCMAUS Pty Ltd. to purchase up to 588,170 warrants pursuant to the Private Placement Warrants
Purchase Agreements, dated as of [•], 2021 (collectively, the “Private Placement Warrants Purchase Agreements”),
and in connection therewith, will issue and deliver up to 4,843,750 warrants (the “Private Warrants”), each whole Private
Warrant entitling its holder to purchase one share of Common Stock (“Private Warrant Shares”, and together with the
Public Warrant Shares, the “Warrant Shares”);

 

WHEREAS,
the Company may issue up to an additional 1,500,000 redeemable warrants in satisfaction of certain working capital loans made by the Company’s
officers, directors, initial stockholders (as defined in the Prospectus) and their affiliates (“Working Capital Warrants”);

 

WHEREAS,
following consummation of the Public Offering, the Company may issue additional warrants (“Post IPO Warrants” and collectively
with the Public Warrants, Private Warrants and Working Capital Warrants, the “Warrants”) in connection with, or following
the consummation by the Company of, an initial business combination;

 

WHEREAS, the Company desires
the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration,
transfer, exchange, redemption and exercise of the Warrants;

 

WHEREAS, the Company desires
to provide for the form, terms and provisions of the Warrants, including the terms upon which they shall be issued and exercised, and
the respective rights, limitation of rights and immunities of the Company, the Warrant Agent and the holders of the Warrants; and

 

     

     

    

 

WHEREAS, all acts and things
have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned by or
on behalf of the Warrant Agent, as provided herein, the legally valid and binding obligations of the Company, and to authorize the execution
and delivery of this Warrant Agreement.

 

NOW, THEREFORE, in consideration
of the mutual agreements herein contained, the parties hereto agree as follows:

 

1.            Appointment
of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants, and the Warrant
Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this Warrant
Agreement.

 

2.            Warrants.

 

2.1           Form of
Warrant. Each Warrant other than a Private Warrant shall be: (a) issued in registered form only, (b) in substantially the
form of Exhibit A hereto, the provisions of which are incorporated herein and (c) signed by, or bear the facsimile signature
of (i) the Chairman of the Board, the Chief Executive Officer, the President or a Vice President and (ii) the Chief Financial
Officer, Treasurer, an Assistant Treasurer, the Secretary or an Assistant Secretary of the Company. In the event the person whose facsimile
signature has been placed upon any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant before such
Warrant is issued, it may be issued with the same effect as if he or she had not ceased to be such at the date of issuance.

 

2.2           Effect
of Countersignature. Unless and until countersigned by the Warrant Agent pursuant to this Warrant Agreement, a Warrant shall be invalid
and of no effect and may not be exercised by the holder thereof.

 

2.3           Registration.

 

2.3.1        Warrant
Register. The Warrant Agent shall maintain books (the “Warrant Register”), for the registration of the original
issuance and transfers of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the Warrants
in the names of the respective holders thereof in such denominations and otherwise in accordance with instructions delivered to the Warrant
Agent by the Company.

 

2.3.2        Registered
Holder. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and treat
the person in whose name such Warrant shall be registered upon the Warrant Register (“Registered Holder”) as the absolute
owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other writing on the Warrant
certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise thereof, and for all other purposes,
and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.

 

     

     

    

 

2.4           Detachability
of Warrants. Each of the securities comprising the Units will begin to trade separately on (i) the 90th day after the effectiveness
of the Registration Statement, or (ii) such earlier date as Chardan Capital Markets, LLC, as representative of the underwriters (the
 “Representative”), shall determine is acceptable (such date, the “Detachment Date”). In no event
will separate trading of the securities comprising the Units commence until the Company (i) files a Current Report on Form 8-K
with the SEC including audited balance sheet reflecting the Company’s receipt of the gross proceeds of the Public Offering and (ii) issues
a press release announcing when such separate trading will begin.

 

2.5           Private
Warrants. The Private Warrants (i) will be exercisable either for cash or on a cashless basis at the holder’s option pursuant
to Section 3.3 hereof and (ii) will not be redeemable by the Company, in either case as long as the Private Warrants
are held by the initial purchasers or any of their permitted transferees (as prescribed in the Private Placement Warrants Purchase Agreements).
The Private Warrants may not be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative,
put, or call transaction that would result in the effective economic disposition of, the Private Warrants (or any securities underlying
the Private Warrants) for a period of one hundred eighty (180) days following the effective date of the Registration Statement to anyone
other than any underwriter and selected dealer participating in the Public Offering and the officers or partners thereof, if all securities
so transferred remain subject to the lock-up restriction set forth above for the remainder of the time period.

 

3.            Terms
and Exercise of Warrants.

 

3.1           Warrant
Price. Each Warrant shall, when countersigned by the Warrant Agent, entitle the Registered Holder thereof, subject to the provisions
of such Warrant and of this Warrant Agreement, to purchase from the Company the number of shares of Common Stock stated therein, at $11.50
per full share, subject to the adjustments provided in Section 4 hereof. The term “Warrant Price” as used in this
Warrant Agreement refers to the price per whole share at which shares of Common Stock may be purchased at the time such Warrant is exercised.
The Public Warrants may only be exercised for a whole number of Warrant Shares by a Registered Holder. The Company in its sole discretion
may lower the Warrant Price (including by allowing “cashless exercise”) at any time prior to the Expiration Date (as defined
below) for a period of not less than twenty (20) business days, provided, that the Company shall provide at least three (3) days
prior written notice of such reduction to Registered Holders of the Warrants and, provided further that any such reduction shall be identical
among all of the Warrants.

 

     

     

    

 

3.2           Duration
of Warrants. A Warrant may be exercised only during the period (“Exercise Period”) commencing on the later to occur
of (i) the completion of the Company’s initial business combination and (ii) 12 months following the closing of the Public
Offering, and terminating at 5:00 p.m., New York City time, on the earlier to occur of (i) (A) five years following the completion
of the Company’s initial business combination, other than the Private Warrants purchased by Chardan Gardiner LLC, and (B) five
years from the effective date of the Registration Statement with respect to the Private Warrants purchased by Chardan Gardiner LLC, provided
that once the Private Warrants are not beneficially owned by Chardan Gardiner LLC or any of its related persons anymore, the Private Warrants
may not be exercised five years following the completion of the Company’s initial business combination, and (ii) the date fixed
for redemption of the Warrants as provided in Section 6 of this Warrant Agreement (“Expiration Date”). Except
with respect to the right to receive the Redemption Price (as set forth in Section 6 hereunder), each Warrant not exercised on or
before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Warrant Agreement
shall cease at the close of business on the Expiration Date. The Company may extend the duration of the Warrants by delaying the Expiration
Date; provided, however, that the Company will provide written notice of not less than 10 days to Registered Holders of such extension
and that such extension shall be identical in duration among all of the then outstanding Warrants. Notwithstanding the above, the Private
Warrants (and the Private Warrant Shares that are issuable upon exercise of the Private Warrants) to be purchased by Chardan Gardiner
LLC have been deemed compensation by Financial Industry Regulatory Authority, Inc. (“FINRA”) and are therefore subject
to a 180-day lock-up described in the following sentence pursuant to FINRA Rule 5110(e)(1) commencing on the effective date
of the Registration Statement as long as Chardan Capital Markets, LLC or any of its related persons beneficially own these Private Warrants.
Pursuant to FINRA Rule 5110(e)(1), the Private Warrants (and the Private Warrant Shares that are issuable upon exercise of the Private
Warrants) purchased by Chardan Gardiner LLC will not be sold during the Public Offering, or sold, transferred, assigned, pledged, or hypothecated,
or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of such
securities by any person for a period of 180 days immediately following the effective date of the Registration Statement, except to any
underwriter and selected dealer participating in the Public Offering made pursuant to the Registration Statement and their bona fide officers
or partners, provided that all such securities so transferred remain subject to the lockup restriction above for the remainder of the
time period.

 

3.3           Exercise
of Warrants.

 

3.3.1        Cash
Exercise. Subject to the provisions of the Warrant and this Warrant Agreement, a Warrant, when countersigned by the Company, may be
exercised by the Registered Holder thereof by surrendering it at the office of the Warrant Agent, or at the office of its successor as
Warrant Agent, currently being:

 

Continental
Stock Transfer & Trust Company

1 State Street, 30th Floor

New York, New York 10004

Attn: Compliance Department

 

with the subscription form, as set forth in the
Warrant, duly executed, and by paying in full, in lawful money of the United States, by certified or bank cashier’s check payable
to the order of the Warrant Agent or by wire transfer to the Warrant Agent’s bank account, the Warrant Price for each whole Warrant
Share as to which the Warrant is exercised and any and all applicable taxes due in connection with the exercise of the Warrant, the exchange
of the Warrant for the Warrant Shares, and the issuance of the Warrant Shares (such exercise, a “Cash Exercise”). A
Cash Exercise in accordance with this Section 3.3.1 is available to the Registered Holder only during such times that there is an
effective registration statement registering the Warrant Shares, with the prospectus contained therein being available for the resale
of the Warrant Shares.

 

3.3.2        Cashless
Exercise. Subject to Section 2.4, notwithstanding anything contained herein to the contrary, if there is no effective registration
statement registering the Warrant Shares on any day the Registered Holder desires to exercise the Warrants and more than 120 days have
passed since the Company completed its initial business combination, the Registered Holder may exercise the Warrants in whole or in part
in lieu of making a cash payment for whole numbers of Warrant Shares, by providing notice to the Chief Financial Officer of the Company
in a subscription form of its election to utilize cashless exercise, in which event the Company shall issue to the holder the number of
Warrant Shares determined as follows:

 

X = Y [(A-B)/A]

 

where:

 

X = the number of Warrant Shares to be issued to the holder.

Y = the number of Warrant Shares with respect to which this
Warrant is being exercised.

A = the fair market value of one share of Common Stock.

B = the Warrant Price.

 

     

     

    

 

The Registered Holder may not exercise any Warrants
in the absence of a registration statement except pursuant to this Section 3.3.2. For purposes of this Section 3.3.2
and Section 4.1, the fair market value of one share of Common Stock is defined as follows:

 

		(i)	if the Company’s shares of Common Stock are listed and traded on the New York Stock Exchange, the
NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market (each, a “Trading Market”),
the fair market value shall be deemed the average reported last sale price of the shares of Common Stock on such Trading Market for the
10 trading days ending on the day prior to the date the subscription form is submitted to the Company in connection with the exercise
of the Warrant; or

 

		(ii)	if the Company’s shares of Common Stock are not listed on a Trading Market, but is traded in the
over-the-counter market, the fair market value shall be deemed to be the average of the bid price on such Trading Market for the 10 trading
days ending on the day prior to the date the subscription form is submitted in connection with the exercise of the Warrant; or

 

		(iii)	if there is no active public market for the Company’s shares of Common Stock, the fair market value
of the shares of Common Stock shall be determined in good faith by the Company’s board of directors.

 

3.3.3      Fractional
Shares. Notwithstanding any provision to the contrary contained in this Warrant Agreement, the Company shall not be required to issue
any fraction of a Warrant Share in connection with the exercise of Warrants, and in any case where the Registered Holder would be entitled
under the terms of the Warrants to receive a fraction of a Warrant Share upon the exercise of such Registered Holder’s Warrants,
issue or cause to be issued only the largest whole number of Warrant Shares issuable on such exercise (and such fraction of a Warrant
Share will be disregarded); provided, that if more than one Warrant certificate is presented for exercise at the same time by the same
Registered Holder, the number of whole Warrant Shares which shall be issuable upon the exercise thereof shall be computed on the basis
of the aggregate number of Warrant Shares issuable on exercise of all such Warrants.

 

     

     

    

 

3.3.4        Issuance
of Certificates. No later than three (3) business days following the exercise of any Warrant and the clearance of the funds in
payment of the Warrant Price pursuant to Section 3.3.1 or cashless exercise pursuant to Section 3.3.2, the Company shall issue,
or cause to be issued, to the Registered Holder of such Warrant a certificate or certificates representing (or at the option of the Registered
Holder, deliver electronically through the facilities of the Depository Trust Corporation) the number of full shares of Common Stock to
which he, she or it is entitled, registered in such name or names as may be directed by him, her or it, and, if such Warrant shall not
have been exercised or surrendered in full, a new countersigned Warrant for the number of shares as to which such Warrant shall not have
been exercised or surrendered. Notwithstanding the foregoing, the Company shall not deliver, or cause to be delivered, any securities
without applicable restrictive legend pursuant to the exercise of a Warrant unless (a) a registration statement under the Securities
Act with respect to the shares of Common Stock issuable upon exercise of such Warrants is effective and a current prospectus relating
to the shares of Common Stock issuable upon exercise of the Warrants is available for delivery to the Registered Holder of the Warrant
or (b) in the opinion of counsel to the Company, the exercise of the Warrants is exempt from the registration requirements of the
Securities Act and such securities are qualified for sale or exempt from qualification under applicable securities laws of the states
or other jurisdictions in which the Registered Holder resides. Warrants may not be exercised by, or securities issued to, any Registered
Holder in any state in which such exercise or issuance would be unlawful. In addition, in no event will the Company be obligated to pay
such Registered Holder any cash consideration upon exercise or otherwise “net cash settle” the Warrant.

 

3.3.5       Valid
Issuance. All shares of Common Stock issued upon the proper exercise or surrender of a Warrant in conformity with this Warrant Agreement
shall be validly issued, fully paid and non-assessable.

 

3.3.6       Date
of Issuance. Each person or entity in whose name any such certificate for shares of Common Stock is issued shall, for all purposes,
be deemed to have become the holder of record of such shares on the date on which the Warrant was surrendered and payment of the Warrant
Price was made, irrespective of the date of delivery of such certificate, except that, if the date of such surrender and payment is a
date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at
the close of business on the next succeeding date on which the stock transfer books are open.

 

     

     

    

 

3.3.7       Maximum
Percentage. A holder of a Warrant may notify the Company in writing in the event it elects to be subject to the provisions contained
in this subsection 3.3.7; however, no holder of a Warrant shall be subject to this subsection 3.3.7 unless he, she or it makes such election.
If the election is made by a holder, the Warrant Agent shall not effect the exercise of the holder’s Warrant, and such holder shall
not have the right to exercise such Warrant, to the extent that after giving effect to such exercise, such person (together with such
person’s affiliates), to the Warrant Agent’s actual knowledge, would beneficially own in excess of 4.99% or 9.99% (or such
other amount as such person may specify) (each, a “Maximum Percentage”) of the shares of Common Stock outstanding immediately
after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially
owned by such person and its affiliates shall include the number of shares of Common Stock issuable upon exercise of the Warrant with
respect to which the determination of such sentence is being made, but shall exclude the shares of Common Stock that would be issuable
upon (x) exercise of the remaining, unexercised portion of the Warrant beneficially owned by such person and its affiliates and (y) exercise
or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such person and its
affiliates (including, without limitation, any convertible notes or convertible preferred shares or warrants) subject to a limitation
on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of
this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of
1934, as amended (the “Exchange Act”). For purposes of the Warrant, in determining the number of outstanding shares
of Common Stock, the holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company’s
most recent annual report on Form 10-K, quarterly report on Form 10-Q, current report on Form 8-K or other public filing
with the SEC as the case may be, (2) a more recent public announcement by the Company, or (3) any other notice by the Company
or the Warrant Agent setting forth the number of shares of Common Stock outstanding. For any reason at any time, upon the written request
of the holder of the Warrant, the Company shall, within two (2) business days, confirm orally and in writing to such holder the number
of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving
effect to the conversion or exercise of equity securities of the Company by the holder and its affiliates since the date as of which such
number of outstanding shares of Common Stock was reported. By written notice to the Company, the holder of a Warrant may from time to
time increase or decrease the Maximum Percentage applicable to such holder to any other percentage specified in such notice; provided,
however, that any such increase shall not be effective until the sixty-first (61st) day after such notice is delivered to the Company.

 

4.            Adjustments.

 

4.1            Stock
Dividends, Splits. If, after the date hereof, and subject to the provisions of Section 4.5 below, the number of outstanding shares
of Common Stock is increased by a stock dividend payable in shares of Common Stock, or by a forward or reverse split of shares of Common
Stock, or other similar event, then, on the effective date of such stock dividend, split or similar event, the number of shares of Common
Stock issuable on exercise of each Warrant shall be increased or decreased in proportion to such increase or decrease in outstanding shares
of Common Stock. A rights offering to all holders of the shares of Common Stock entitling holders to purchase shares of Common Stock at
a price less than the fair market value shall be deemed a stock dividend of a number of shares of Common Stock equal to the product of
(i) the number of shares of Common Stock actually sold in such rights offering (or issuable under any other equity securities sold
in such rights offering that are convertible into or exercisable for the shares of Common Stock) multiplied by (ii) one (1) minus
the quotient of (x) the price per share of Common Stock paid in such rights offering divided by (y) the fair market value. For
purposes of this subsection 4.1, if the rights offering is for securities convertible into or exercisable for shares of Common Stock,
in determining the price payable for the shares of Common Stock, there shall be taken into account any consideration received for such
rights, as well as any additional amount payable upon exercise or conversion.

 

     

     

    

 

4.2            Aggregation
of Shares. If, after the date hereof, and subject to the provisions of Section 4.6, the number of outstanding shares of Common
Stock is decreased by a consolidation, combination or reclassification of shares of Common Stock or other similar event, then, on the
effective date of such consolidation, combination, reclassification or similar event, the number of shares of Common Stock issuable on
exercise of each Warrant shall be decreased in proportion to such decrease in outstanding shares of Common Stock.

 

4.3           Extraordinary
Dividends. If the Company, at any time while the Warrants (or rights to purchase the Warrants) are outstanding and unexpired, shall
pay a dividend or make a distribution in cash, securities or other assets to the holders of the shares of Common Stock on account of such
shares of Common Stock (or other shares of the Company’s capital stock into which the Warrants are convertible), other than (a) as
described in subsection 4.1 above, (b) Ordinary Cash Dividends (as defined below), (c) to satisfy the conversion rights of the
holders of the shares of Common Stock in connection with a proposed initial business combination or vote to extend the time period to
complete an initial business combination, (d) as a result of the repurchase of shares of Common Stock by the Company in connection
with an initial business combination or as otherwise permitted by the Investment Management Trust Agreement between the Company and the
Warrant Agent dated of even date herewith or (e) in connection with the Company’s liquidation and the distribution of its assets
upon its failure to consummate a business combination (any such non-excluded event being referred to herein as an “Extraordinary
Dividend”), then the Warrant Price shall be decreased, effective immediately after the effective date of such Extraordinary Dividend,
by the amount of cash and the fair market value (as determined by the Company’s board of directors, in good faith) of any securities
or other assets paid on each share of Common Stock in respect of such Extraordinary Dividend. For purposes of this subsection 4.3, “Ordinary
Cash Dividends” means any cash dividend or cash distribution which, when combined on a per share basis with the per share amounts
of all other cash dividends and cash distributions paid on the shares of Common Stock during the 365-day period ending on the date of
declaration of such dividend or distribution (as adjusted to appropriately reflect any of the events referred to in other subsections
of this Section 4 and excluding cash dividends or cash distributions that resulted in an adjustment to the Warrant Price or to the
number of shares of Common Stock issuable on exercise of each Warrant) does not exceed $0.50 (being 5% of the offering price of the Units
in the Public Offering).

 

4.4           Adjustments
in Exercise Price.

 

4.4.1       Whenever
the number of shares of Common Stock purchasable upon the exercise of the Warrants is adjusted, as provided in Sections 4.1 and 4.2 above,
the Warrant Price shall be adjusted (to the nearest cent) by multiplying such Warrant Price, immediately prior to such adjustment, by
a fraction, (a) the numerator of which shall be the number of shares of Common Stock purchasable upon the exercise of the Warrants
immediately prior to such adjustment, and (b) the denominator of which shall be the number of shares of Common Stock so purchasable
immediately thereafter.

 

     

     

    

 

4.4.2        If
(i) the Company issues additional shares of Common Stock or equity-linked securities for capital raising purposes in connection with
the closing of its initial business combination at an issue price or effective issue price of less than $9.20 per share of Common Stock
(with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case
of any such issuance to the Company’s initial stockholders or their affiliates, without taking into account any founder shares (as
defined in the Prospectus) or Private Warrants held by them, as applicable, prior to such issuance) (the “newly issued price”),
(y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon,
available for the funding of the Company’s initial business combination on the date of the completion of its initial business combination
(net of redemptions), and (z) the volume-weighted average trading price of the Common Stock during the 20 trading day period starting
on the trading day prior to the day on which the Company completes its initial business combination (such price, the “Market Value”)
is below $9.50 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher
of the Market Value and the newly issued price and the $16.50 per share redemption trigger price will be adjusted (to the nearest cent)
to be equal to 165% of the higher of the Market Value and the newly issued price.

 

4.5           Replacement
of Securities upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding shares of Common
Stock (other than a change covered by Sections 4.1, 4.2 or 4.3 hereof or one that solely affects the par value of such shares of Common
Stock), or, in the case of any merger or consolidation of the Company with or into another corporation (other than a consolidation or
merger in which the Company is the continuing corporation and that does not result in any reclassification or reorganization of the outstanding
shares of Common Stock), or, in the case of any sale or conveyance to another corporation or entity of the assets or other property of
the Company as an entirety or substantially as an entirety, in connection with which the Company is dissolved, the Registered Holders
shall thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and
in lieu of the shares of Common Stock of the Company immediately theretofore purchasable and receivable upon the exercise of the rights
represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification,
reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the Registered Holder would have
received if such Registered Holder had exercised his, her or its Warrant(s) immediately prior to such event; and if any reclassification
or reorganization also results in a change in shares of Common Stock covered by Sections 4.1, 4.2 or 4.3, then such adjustment shall be
made pursuant to Sections 4.1, 4.2, 4.3 and this Section 4.5. The provisions of this Section 4.5 shall similarly apply to successive
reclassifications, reorganizations, mergers or consolidations, sales or other transfers. In no event will the Warrant Price be reduced
to less than the par value per share issuable upon exercise of the Warrants.

 

4.6           Notices
of Changes in Warrant. Upon every adjustment of the Warrant Price or the number of shares issuable upon exercise of a Warrant, the
Company shall give written notice thereof to the Warrant Agent, which notice shall state the Warrant Price resulting from such adjustment
and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of a Warrant, setting forth
in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon the occurrence of any event specified
in Sections 4.1 – 4.5 the Company shall give written notice to each Registered Holder, at the last address set forth for
such Registered Holder in the Warrant Register, of the record date or the effective date of the event. Failure to give such notice, or
any defect therein, shall not affect the legality or validity of such event.

 

     

     

    

 

4.7           Form of
Warrant. The form of Warrant need not be changed because of any adjustment pursuant to this Section 4, and Warrants issued after
such adjustment may state the same Warrant Price and the same number of shares as is stated in the Warrants initially issued pursuant
to this Warrant Agreement. However, the Company may, at any time, in its sole discretion, make any change in the form of Warrant that
the Company may deem appropriate and that does not affect the substance thereof, and any Warrant thereafter issued or countersigned, whether
in exchange or substitution for an outstanding Warrant or otherwise, may be in the form as so changed.

 

4.8           Notice
of Certain Transactions. In the event that the Company shall (a) offer to holders of all its shares of Common Stock rights to
subscribe for or to purchase any securities convertible into shares of Common Stock or shares of stock of any class or any other securities,
rights or options, (b) issue any rights, options or warrants entitling all the holders of shares of Common Stock to subscribe for
shares of Common Stock, or (c) make a tender offer, redemption offer or exchange offer with respect to the shares of Common Stock,
the Company shall send to the Registered Holders a notice of such action or offer. Such notice shall be mailed to the Registered Holders
at their addresses as they appear in the Warrant Register, which shall specify the record date for the purposes of such dividend, distribution
or rights, or the date such issuance or event is to take place and the date of participation therein by the holders of shares of Common
Stock, if any such date is to be fixed, and shall briefly indicate the effect of such action on the shares of Common Stock and on the
number and kind of any other shares of stock and on other property, if any, and the number of shares of Common Stock and other property,
if any, issuable upon exercise of each Warrant and the Warrant Price after giving effect to any adjustment pursuant to this Section 4
which would be required as a result of such action. Such notice shall be given as promptly as practicable after the Company has taken
any such action.

 

5.            Transfer
and Exchange of Warrants.

 

5.1           Transfer
of Warrants. Prior to the Detachment Date, the Warrants may be transferred or exchanged only together with the Unit in which such
Warrant is included, and only for the purpose of effecting, or in conjunction with, a transfer or exchange of such Unit. Furthermore,
each transfer of a Unit on the register relating to such Units shall operate also to transfer the Warrants included in such Unit. From
and after the Detachment Date, this Section 5.1 will have no further force and effect.

 

5.2           Registration
of Transfer. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant into the Warrant Register,
upon surrender of such Warrant for transfer, properly endorsed with signatures properly guaranteed and accompanied by appropriate instructions
for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants shall be issued and the old Warrant
shall be cancelled by the Warrant Agent. The Warrants so cancelled shall be delivered by the Warrant Agent to the Company from time to
time upon the Company’s request.

 

5.3           Procedure
for Surrender of Warrants. Warrants may be surrendered to the Warrant Agent, together with a written request for exchange or transfer,
and, thereupon, the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered Holder of the
Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that, in the event a Warrant surrendered
for transfer bears a restrictive legend, the Warrant Agent shall not cancel such Warrant and shall issue new Warrants in exchange therefor
until the Warrant Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether
the new Warrants must also bear a restrictive legend.

 

     

     

    

 

5.4           Fractional
Warrants. The Warrant Agent shall not be required to effect any registration of transfer or exchange which will result in the issuance
of a warrant certificate for a fraction of a warrant.

 

5.5           Service
Charges. No service charge shall be made for any exchange or registration of transfer of Warrants.

 

5.6           Warrant
Execution and Countersignature. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with the terms
of this Warrant Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5, and the Company, whenever
required by the Warrant Agent, will supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose.

 

6.            Redemption.

 

6.1           Redemption.
All (and not less than all) of the outstanding Warrants may be redeemed, in whole and not in part, at the option of the Company, at any
time from and after the Warrants become exercisable, and prior to their expiration, at the office of the Warrant Agent, upon the notice
referred to in Section 6.2, at the price of $0.01 per Warrant (“Redemption Price”); provided that the last sales
price of the shares of Common Stock has been equal to or greater than $16.50 per share (subject to adjustment for splits, dividends, recapitalizations
and other similar events), for any twenty (20) trading days within a thirty (30) trading day period ending on the third business day prior
to the date on which notice of redemption is given and provided further that there is a current registration statement in effect with
respect to the shares of Common Stock underlying the Warrants for each day in the aforementioned 30-day trading period and continuing
each day thereafter until the Redemption Date (defined below). For avoidance of doubt, if and when the warrants become redeemable by the
Company under this Section 6.1, the Company may exercise its redemption right, even if it is unable to register or qualify the Warrant
Shares for sale under all applicable state securities laws.

 

6.2           Date
Fixed for, and Notice of, Redemption. In the event the Company shall elect to redeem all of the Warrants, the Company shall fix a
date for the redemption (the “Redemption Date”). Notice of redemption shall be mailed by first class mail, postage
prepaid, by the Company not less than 30 days prior to the date fixed for redemption to the Registered Holders of the Warrants to be redeemed
at their last addresses as they shall appear on the Warrant Register. Any notice mailed in the manner herein provided shall be conclusively
presumed to have been duly given, whether or not the Registered Holder received such notice.

 

     

     

    

 

6.3           Exercise
After Notice of Redemption. The Warrants may be exercised in accordance with Section 3 of this Warrant Agreement at any time
after notice of redemption shall have been given by the Company pursuant to Section 6.2 hereof and prior to the Redemption Date;
provided that the Company may require the Registered Holder who desires to exercise the Warrant to elect cashless exercise as set forth
under Section 3.3.2, and such Registered Holder must exercise the Warrants on a cashless basis if the Company so requires. On and
after the Redemption Date, the Registered Holder of the Warrants shall have no further rights except to receive, upon surrender of the
Warrants, the Redemption Price.

 

6.4           No
Other Rights to Cash Payment. Except for a redemption in accordance with this Section 6, no Registered Holder of any Warrant
shall be entitled to any cash payment whatsoever from the Company in connection with the ownership, exercise or surrender of any Warrant
under this Warrant Agreement.

 

7.            Other
Provisions Relating to Rights of Registered Holders of Warrants.

 

7.1           No
Rights as Stockholder. A Warrant does not entitle the Registered Holder thereof to any of the rights of a stockholder of the Company,
including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote or to consent
or to receive notice as stockholders in respect of the meetings of stockholders or the election of directors of the Company or any other
matter.

 

7.2           Lost,
Stolen Mutilated or Destroyed Warrants. If any Warrant is lost, stolen, mutilated or destroyed, the Company and the Warrant Agent
may, on such terms as to indemnity or otherwise as they may in their discretion impose (which terms shall, in the case of a mutilated
Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor and date as the Warrant so lost, stolen, mutilated
or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not the allegedly lost,
stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone.

 

7.3           Reservation
of Shares of Common Stock. The Company shall at all times reserve and keep available a number of its authorized but unissued shares
of Common Stock that will be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Warrant Agreement.

 

7.4           Registration
of Shares of Common Stock. The Company agrees that as soon as practicable after the closing of a business combination, it shall use
its best efforts to file with the SEC a registration statement for the registration under the Securities Act of the shares of Common Stock
issuable upon exercise of the Warrants, and to cause the same to become effective and to maintain the effectiveness of such registration
statement, and a current prospectus relating thereto, until the expiration of the Warrants in accordance with the provisions of this Warrant
Agreement. In addition, the Company agrees to use its best efforts to register the shares of Common Stock issuable upon exercise of the
Warrants under state blue sky laws, to the extent an exemption is not available.

 

8.            Concerning
the Warrant Agent and Other Matters.

 

8.1           Payment
of Taxes. The Company will, from time to time, promptly pay all taxes and charges that may be imposed upon the Company or the Warrant
Agent in respect of the issuance or delivery of shares of Common Stock upon the exercise of Warrants, but the Company shall not be obligated
to pay any transfer taxes in respect of the Warrants or such shares.

 

     

     

    

 

8.2           Resignation,
Consolidation, or Merger of Warrant Agent.

 

8.2.1        Appointment
of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged
from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the office
of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint, in writing, a successor
Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of 30 days after it has
been notified in writing of such resignation or incapacity by the Warrant Agent or by the Registered Holder of the Warrant (who shall,
with such notice, submit his, her or its Warrant for inspection by the Company), then the Registered Holder of any Warrant may apply to
the Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent. Any successor
Warrant Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing under the laws of the
State of New York, in good standing and having its principal office in the Borough of Manhattan, City and State of New York, and be authorized
under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state authorities. After appointment,
any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties and obligations of its predecessor
Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed; but, if for any reason
it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument
transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and, upon
request of any successor Warrant Agent, the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for
more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties
and obligations.

 

8.2.2       Notice
of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the
predecessor Warrant Agent and the transfer agent for the shares of Common Stock not later than the effective date of any such appointment.

 

8.2.3        Merger
or Consolidation of Warrant Agent. Any corporation into which the Warrant Agent may be merged or with which it may be consolidated
or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant
Agent under this Warrant Agreement without any further act on the part of the Company or the Warrant Agent.

 

8.3           Fees
and Expenses of Warrant Agent.

 

8.3.1        Remuneration.
The Company agrees to pay the Warrant Agent reasonable remuneration for its services as Warrant Agent hereunder and will reimburse the
Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its duties hereunder.

 

     

     

    

 

8.3.2        Further
Assurances. The Company agrees to perform, execute, acknowledge and deliver, or cause to be performed, executed, acknowledged and
delivered, all such further and other acts, instruments and assurances as may reasonably be required by the Warrant Agent for the carrying
out or performing of the provisions of this Warrant Agreement.

 

8.4           Liability
of Warrant Agent.

 

8.4.1        Reliance
on Company Statement. Whenever, in the performance of its duties under this Warrant Agreement, the Warrant Agent shall deem it necessary
or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact
or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established
by a statement signed by the Chief Executive Officer, Chief Financial Officer or Chairman of the Board of the Company and delivered to
the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the
provisions of this Warrant Agreement.

 

8.4.2        Indemnity.
The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith. The Company agrees to
indemnify the Warrant Agent and hold it harmless against any and all liabilities, including judgments, costs and reasonable counsel fees,
for anything done or omitted by the Warrant Agent in the execution of this Warrant Agreement, except as a result of the Warrant Agent’s
gross negligence, willful misconduct or bad faith.

 

8.4.3        Exclusions.
The Warrant Agent shall have no responsibility with respect to the validity of this Warrant Agreement or with respect to the validity
or execution of any Warrant (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant
or condition contained in this Warrant Agreement or in any Warrant; nor shall it be responsible to make any adjustments required under
the provisions of Section 4 hereof or responsible for the manner, method or amount of any such adjustment or the ascertaining of
the existence of facts that would require any such adjustment; nor shall it, by any act hereunder, be deemed to make any representation
or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant to this Warrant Agreement or any
Warrant or as to whether any shares of Common Stock will when issued be valid and fully paid and non-assessable.

 

8.5          Acceptance
of Agency. The Warrant Agent hereby accepts the agency established by this Warrant Agreement and agrees to perform the same upon the
terms and conditions herein set forth and, among other things, shall account promptly to the Company with respect to Warrants exercised
and concurrently account for, and pay to the Company, all moneys received by the Warrant Agent for the purchase of shares of the Company’s
shares of Common Stock through the exercise of Warrants.

 

8.6          Waiver.
The Warrant Agent hereby waives any right of set-off or any other right, title, interest or claim of any kind (“Claim”) in
or to any distribution of the Trust Account (as defined in that certain Investment Management Trust Agreement, dated as of the date hereof,
by and between the Company and the Warrant Agent as trustee thereunder) and hereby agrees not to seek recourse, reimbursement, payment
or satisfaction for any Claim against the Trust Account for any reason whatsoever.

 

     

     

    

 

9.            Miscellaneous
Provisions.

 

9.1          Successors.
All the covenants and provisions of this Warrant Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure
to the benefit of their respective successors and assigns.

 

9.2          Notices.
Any notice, statement or demand authorized by this Warrant Agreement to be given or made by the Warrant Agent or by the Registered Holder
of any Warrant to or on the Company shall be delivered by hand or sent by registered or certified mail or overnight courier service, addressed
(until another address is filed in writing by the Company with the Warrant Agent) as follows:

 

Gardiner Healthcare Acquisitions Corp.

3107 Warrington Road

Shaker Heights, OH 44120

Attn: Chief Executive Officer

 

with a copy (which shall not constitute notice) to:

 

Reed Smith
LLP

506 Carnegie Center

Suite 300

Princeton,
New Jersey 08540

Attn: Edward
P. Bromley III, Esq.

 

Email: ebromley@reedsmith.com

 

Any notice, statement or demand authorized by
this Warrant Agreement to be given or made by the Registered Holder of any Warrant or by the Company to or on the Warrant Agent shall
be delivered by hand or sent by registered or certified mail or overnight courier service, addressed (until another address is filed in
writing by the Warrant Agent with the Company), as follows:

 

Continental
Stock Transfer & Trust Company

1 State Street, 30th Floor

New York, New York 10004

 

Any notice, sent pursuant to this Warrant Agreement
shall be effective, if delivered by hand, upon receipt thereof by the party to whom it is addressed, if sent by overnight courier, on
the next business day of the delivery to the courier, and if sent by registered or certified mail on the third day after registration
or certification thereof.

 

     

     

    

 

9.3             
Applicable Law. The validity, interpretation, and performance of this Warrant Agreement and of the Warrants shall
be governed in all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result
in the application of the substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim against
it arising out of or relating in any way to this Warrant Agreement, including under the Securities Act, shall be brought and enforced
in the courts of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits
to such jurisdiction, which jurisdiction shall be the exclusive forum for any such action, proceeding or claim. The Company hereby waives
any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Notwithstanding the foregoing, the
provisions of this paragraph will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other
claim for which the federal district courts of the United States of America are the sole and exclusive forum. Any person or entity purchasing
or otherwise acquiring any interest in the Warrants shall be deemed to have notice of and to have consented to the forum provisions in
this Section 9.3. If any action, the subject matter of which is within the scope of the forum provisions above, is filed in a court other
than a court located within the State of New York or the United States District Court for the Southern District of New York (a “Foreign
Action”) in the name of any warrant holder, such warrant holder shall be deemed to have consented to: (x) the personal jurisdiction
of the state and federal courts located within the State of New York or the United States District Court for the Southern District of
New York in connection with any action brought in any such court to enforce the forum provisions (an “Enforcement Action”),
and (y) having service of process made upon such warrant holder in any Enforcement Action by service upon such warrant holder’s
counsel in the Foreign Action as agent for such warrant holder.

 

9.4           Persons
Having Rights under this Warrant Agreement. Nothing in this Warrant Agreement expressed and nothing that may be implied from any of
the provisions hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than the parties
hereto and the Registered Holders of the Warrants and, for the purposes of Sections 2.5 hereof, the Representative and the underwriters,
any right, remedy, or claim under or by reason of this Warrant Agreement or of any covenant, condition, stipulation, promise, or agreement
hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Warrant Agreement shall be for the sole and
exclusive benefit of the parties hereto and their successors and assigns and of the Registered Holders of the Warrants.

 

9.5           Examination
of the Warrant Agreement. A copy of this Warrant Agreement shall be available at all reasonable times at the office of the Warrant
Agent in the Borough of Manhattan, City and State of New York, for inspection by the Registered Holder of any Warrant. The Warrant Agent
may require any such Registered Holder to submit his, her or its Warrant for inspection.

 

9.6           Counterparts-
Facsimile Signatures. This Warrant Agreement may be executed in any number of counterparts, and each of such counterparts shall, for
all purposes, be deemed to be an original, and all such counterparts shall together constitute one and the same instrument. Facsimile
signatures shall constitute original signatures for all purposes of this Warrant Agreement.

 

9.7           Effect
of Headings. The section headings herein are for convenience only and are not part of this Warrant Agreement and shall not affect
the interpretation thereof

 

     

     

    

 

9.8           Amendments.
This Warrant Agreement and any Warrant certificate may be amended by the parties hereto by executing a supplemental warrant agreement,
without the consent of any of the Warrant holders, for the purpose of (i) curing any ambiguity, or curing, correcting or supplementing
any defective provision contained herein, or making any other provisions with respect to matters or questions arising under this Warrant
Agreement that is not inconsistent with the provisions of this Warrant Agreement or the Warrant certificates, (ii) evidencing the
succession of another corporation to the Company and the assumption by any such successor of the covenants of the Company contained in
this Warrant Agreement and the Warrants, (iii) evidencing and providing for the acceptance of appointment by a successor Warrant
Agent with respect to the Warrants, (iv) adding to the covenants of the Company for the benefit of the Registered Holders or surrendering
any right or power conferred upon the Company under this Warrant Agreement, or (viii) amending this Warrant Agreement and the Warrants
in any manner that the Company may deem to be necessary or desirable and that will not adversely affect the interests of the Registered
Holders in any material respect. All other modifications or amendments to this Warrant Agreement, including any amendment to increase
the Warrant Price or shorten the Exercise Period, shall require the written consent of the Registered Holders of a majority of the then
outstanding Warrants. Notwithstanding the foregoing, the Company may extend the duration of the Exercise Period in accordance with Section 3.2
without such consent.

 

9.9           Severability.
This Warrant Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect
the validity or enforceability of this Warrant Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid
or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Warrant Agreement a provision
as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

 

[SIGNATURE PAGE FOLLOWS]

 

     

     

    

 

IN WITNESS WHEREOF, this Warrant
Agreement has been duly executed by the parties hereto as of the day and year first above written.

 

	 	GARDINER HEALTHCARE ACQUISITIONS CORP.
	 	 
	 	 
	 	By: 	                            
	 	Name: Marc F. Pelletier
	 	Title: Chief Executive Officer
	 	 
	 	 
	 	 
	 	CONTINENTAL STOCK TRANSFER & TRUST COMPANY
	 	 
	 	 
	 	By: 	 
	 	Name: [•]
	 	Title: [•]

 

[Signature Page to Warrant Agreement]

 

     

     

    

 

Exhibit A

 

Form of Warrant

 

 

 

See attached.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}]]